Literature DB >> 16999221

Nitric oxide and the vascular endothelium.

S Moncada1, E A Higgs.   

Abstract

The vascular endothelium synthesises the vasodilator and anti-aggregatory mediator nitric oxide (NO) from L-arginine. This action is catalysed by the action of NO synthases, of which two forms are present in the endothelium. Endothelial (e)NOS is highly regulated, constitutively active and generates NO in response to shear stress and other physiological stimuli. Inducible (i)NOS is expressed in response to immunological stimuli, is transcriptionally regulated and, once activated, generates large amounts of NO that contribute to pathological conditions. The physiological actions of NO include the regulation of vascular tone and blood pressure, prevention of platelet aggregation and inhibition of vascular smooth muscle proliferation. Many of these actions are a result of the activation by NO of the soluble guanylate cyclase and consequent generation of cyclic guanosine monophosphate (cGMP). An additional target of NO is the cytochrome c oxidase, the terminal enzyme in the electron transport chain, which is inhibited by NO in a manner that is reversible and competitive with oxygen. The consequent reduction of cytochrome c oxidase leads to the release of superoxide anion. This may be an NO-regulated cell signalling system which, under certain circumstances, may lead to the formation of the powerful oxidant species, peroxynitrite, that is associated with a variety of vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999221     DOI: 10.1007/3-540-32967-6_7

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  101 in total

Review 1.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

2.  Dynamic ligand exchange in soluble guanylyl cyclase (sGC): implications for sGC regulation and desensitization.

Authors:  Ah-Lim Tsai; Vladimir Berka; Iraida Sharina; Emil Martin
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

3.  Role of endothelin-1 in the hyper-responsiveness to nitrovasodilators following acute NOS inhibition.

Authors:  Stephane L Bourque; Heather A Whittingham; Susan E Brien; Sandra T Davidge; Michael A Adams
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Simulation of NO and O2 transport facilitated by polymerized hemoglobin solutions in an arteriole that takes into account wall shear stress-induced NO production.

Authors:  Yipin Zhou; Pedro Cabrales; Andre F Palmer
Journal:  Biophys Chem       Date:  2012-01-09       Impact factor: 2.352

5.  Potential risks of nitric oxide inhibition in spinal cord injury.

Authors:  Nosratola D Vaziri
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

6.  Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans.

Authors:  S C Erzurum; S Ghosh; A J Janocha; W Xu; S Bauer; N S Bryan; J Tejero; C Hemann; R Hille; D J Stuehr; M Feelisch; C M Beall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-30       Impact factor: 11.205

Review 7.  Non-coding RNA regulation of endothelial and macrophage functions during atherosclerosis.

Authors:  Binod Aryal; Yajaira Suárez
Journal:  Vascul Pharmacol       Date:  2018-03-15       Impact factor: 5.773

Review 8.  MicroRNAs in endothelial cell homeostasis and vascular disease.

Authors:  Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Curr Opin Hematol       Date:  2018-05       Impact factor: 3.284

9.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

10.  Activation of aminoimidazole carcinogens by nitrosation: mutagenicity and nucleotide adducts.

Authors:  Terry V Zenser; Vijaya M Lakshmi; Herman A J Schut; Hui-jia Zhou; P David Josephy
Journal:  Mutat Res       Date:  2009-03-17       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.